Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A PHASE 1, OPEN-LABEL, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF NC525 IN SUBJECTS WITH ADVANCED MYELOID NEOPLASMS

Principal Investigator: Griffiths, Elizabeth A

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with
Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive
Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

Principal Investigator: Levine, Ellis G

A022104:THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II/III TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY REGARDING CLINICAL COMPLETE RESPONSE AND DISEASE-FREE SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

Principal Investigator: Vadehra, Deepak

Respiratory Muscle Training During Breast Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity

Principal Investigator: Gandhi, Shipra

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors

Principal Investigator: Yau, Edwin H

A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

Principal Investigator: Gandhi, Shipra

PHASE 1/2 STUDY OF REGN4336 (A PSMAXCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Principal Investigator: Chatta, Gurkamal S

A Phase 1 Study to Evaluate the Safety and Tolerability of a 2-component autologous CD19 CAR T cell therapy (STK-009 and SYNCAR-001) in Subjects with Relapsed or Refractory CD19+ Hematologic Malignancies.

Principal Investigator: Cortese, Matthew J

CGT9486-21-301 (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS

Principal Investigator: Gupta, Ajay

Low-intensity Mechanical Stimulation for Hematologic Malignancy Patients

Principal Investigator: Herr, Megan M

Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography

Principal Investigator: O'Connor, Richard J

EAY191; Molecular Analysis for Combination Therapy Choice
(ComboMATCH)

Principal Investigator: Levine, Ellis G

A Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel in company-sponsored clinical studies

Principal Investigator: Hillengass, Jens

A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

Principal Investigator: Griffiths, Elizabeth A

Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy

Principal Investigator: Wang, Eunice S

NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER

Principal Investigator: Fung-Kee-Fung, Simon

Phase I Study of the Safety of Intracavitary Photodynamic Therapy (PDT) of the Brain Bordering Resected Recurrent Glioblastoma or Gliosarcoma Using Intravenous Photobac® and a Balloon Light Applicator

Principal Investigator: Fenstermaker, Robert A

NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH
CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

Principal Investigator: Singh, Anurag K

Pilot Study of Episodic Future Thinking among Cigarette Smokers

Principal Investigator: Sheffer, Christine E

(ASCT2031) A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or…

Principal Investigator: Twist, Clare J

(S1918) A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade…

Principal Investigator: Cortese, Matthew J

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

Principal Investigator: Wang, Eunice S

Weight loss interventions to reduce cancer progression in prostate cancer patients under active surveillance

Principal Investigator: Yeary, Karen H

Randomized Phase 2 Trial of APL-2 with Pembrolizumab vs. APL-2 with Pembrolizumab and Bevacizumab vs. Bevacizumab alone in Patients with Recurrent Ovarian Cancer and Persistent Malignant Effusion

Principal Investigator: Zsiros, Emese

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT)

Principal Investigator: Buxbaum, Nataliya P